ATOS was a 12-month prospective observational study in 18 countries outside US and Western Europe in insulin-naïve adults with T2DM, uncontrolled (HbA1c >7-≤11%) on ≥1 oral anti-hyperglycemic drug. This subgroup analysis of ATOS compared the effectiveness and safety of Gla-300 in older (≥70 years [Y]; N=514) and younger (<70 Y; N=3908) adults. People aged ≥70 Y had a longer duration of T2DM and more comorbidities than those aged <70 Y. Physician-set individualized HbA1c (%) goals at baseline in the <70 vs. ≥70 Y groups were <7: 14.6 vs. 6.2%; 7-<7.5: 72.9 vs. 52.1%; 7.5-<8: 9.3 vs. 30.9%; ≥8: 3.2 vs. 10.7%. HbA1c target achievement was higher in the older population than in the <70 Y age group: Month 6 (32.3%, vs. 24.2%) and Month 12 (53.2% vs. 43.4%). HbA1c reductions from baseline to Month 6 (-1.48 vs. -1.51%) and Month 12 (-1.76 vs. -1.89%) were similar in both groups. A very low rate of hypoglycemia was reported, although numerically higher in ≥70 Y group. Increases in the Gla-300 dose was similar across the groups. Incidence of any and serious treatment-emergent adverse events was low. Consistent results were observed in subgroup of <65 vs. ≥65 Y. Initiation of Gla-300 in the older adults is effective in achieving their pre-defined HbA1c goals with low risk of hypoglycemia in both older and younger adults with T2DM.
G. R. Galstyan: None. A. Tirosh: Advisory Panel; Self; AstraZeneca, Eli Lilly and Company, Novo Nordisk, Sanofi, Consultant; Self; DreaMed Diabetes, Ltd. H. Vargas-uricoechea: Advisory Panel; Spouse/Partner; Sanofi. M. N. Mabunay: Employee; Self; Sanofi, Stock/Shareholder; Self; Sanofi. M. Coudert: Employee; Self; Sanofi. V. Pilorget: Employee; Self; Sanofi. N. Khan: None.